Douglas J. Hsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Douglas J. Hsu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Bartolome R. Celli
1 shared publicationCrystal M. North
1 shared publicationEllen P. McCarthy
Department of Medicine Beth Israel Deaconess Medical Center Boston MA USA
1 shared publicationHufeng Zhou
Department of Medicine, Brigham and Women's Hospital, Boston, MA; Department of Microbiology and Immunobiology, Harvard University, Cambridge, MA
1 shared publicationJennifer P. Stevens
Department of Medicine Beth Israel Deaconess Medical Center Boston MA USA
1 shared publicationKenneth J. Mukamal
Department of Medicine Beth Israel Deaconess Medical Center Boston MA USA
1 shared publication
Latest Publications
Hospitalizations, costs and outcomes associated with heroin and prescription opioid overdoses in the United States 2001–12
Background and aims: The full burden of the opioid epidemic on US hospitals has not been described. We aimed to estimate how heroin (HOD) and prescription opioid (POD) overdose‐associated admissions, costs, outcomes and patient characteristics have changed from 2001 to 2012. Design: Retrospective cohort study of hospital admissions from the National Inpatient Sample (NIS). Setting: United States of America. Participants: Hospital admissions in patients aged 18 years or older admitted with a diagnosis of HOD or POD. The NIS sample included 94 492 438 admissions from 2001 to 2012. The final unweighted study sample included 138 610 admissions (POD: 122 147 and HOD: 16 463). Measurements: Primary outcomes were rates of admissions per 100 000 people using US Census Bureau annual estimates. Other outcomes included in‐patient mortality, hospital length‐of‐stay, cumulative and mean hospital costs and patient demographics. All analyses were weighted to provide national estimates. Findings: Between 2001 and 2012, an estimated 663 715 POD and HOD admissions occurred nation‐wide. HOD admissions increased 0.11 per 100 000 people per year [95% confidence interval (CI) = 0.04, 0.17], while POD admissions increased 1.25 per 100 000 people per year (95% CI = 1.15, 1.34). Total in‐patient costs increased by $4.1 million dollars per year (95% CI = 2.7, 5.5) for HOD admissions and by $46.0 million dollars per year (95% CI = 43.1, 48.9) for POD admissions, with an associated increase in hospitalization costs to more than $700 million annually. The adjusted odds of death in the POD group declined modestly per year [odds ratio (OR) = 0.98, 95% CI = 0.97, 0.99], with no difference in HOD mortality or length‐of‐stay. Patients with POD were older, more likely to be female and more likely to be white compared with HOD patients. Conclusions: Rates and costs of heroin and prescription opioid overdose related admissions in the United States increased substantially from 2001 to 2012. The rapid and ongoing rise in both numbers of hospitalizations and their costs suggests that the burden of POD may threaten the infrastructure and finances of US hospitals.
Hospitalizations, costs and outcomes associated with heroin and prescription opioid overdoses in the United States 2001–12
Background and aims: The full burden of the opioid epidemic on US hospitals has not been described. We aimed to estimate how heroin (HOD) and prescription opioid (POD) overdose‐associated admissions, costs, outcomes and patient characteristics have changed from 2001 to 2012. Design: Retrospective cohort study of hospital admissions from the National Inpatient Sample (NIS). Setting: United States of America. Participants: Hospital admissions in patients aged 18 years or older admitted with a diagnosis of HOD or POD. The NIS sample included 94 492 438 admissions from 2001 to 2012. The final unweighted study sample included 138 610 admissions (POD: 122 147 and HOD: 16 463). Measurements: Primary outcomes were rates of admissions per 100 000 people using US Census Bureau annual estimates. Other outcomes included in‐patient mortality, hospital length‐of‐stay, cumulative and mean hospital costs and patient demographics. All analyses were weighted to provide national estimates. Findings: Between 2001 and 2012, an estimated 663 715 POD and HOD admissions occurred nation‐wide. HOD admissions increased 0.11 per 100 000 people per year [95% confidence interval (CI) = 0.04, 0.17], while POD admissions increased 1.25 per 100 000 people per year (95% CI = 1.15, 1.34). Total in‐patient costs increased by $4.1 million dollars per year (95% CI = 2.7, 5.5) for HOD admissions and by $46.0 million dollars per year (95% CI = 43.1, 48.9) for POD admissions, with an associated increase in hospitalization costs to more than $700 million annually. The adjusted odds of death in the POD group declined modestly per year [odds ratio (OR) = 0.98, 95% CI = 0.97, 0.99], with no difference in HOD mortality or length‐of‐stay. Patients with POD were older, more likely to be female and more likely to be white compared with HOD patients. Conclusions: Rates and costs of heroin and prescription opioid overdose related admissions in the United States increased substantially from 2001 to 2012. The rapid and ongoing rise in both numbers of hospitalizations and their costs suggests that the burden of POD may threaten the infrastructure and finances of US hospitals.
- Open Access
- 1 January 2016
- Published by COPD Foundation in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
- Vol. 3 (3) , 620-627
Identification of Barriers to Influenza Vaccination in Patients with Chronic Obstructive Pulmonary Disease: Analysis of the 2012 Behavioral Risk Factors Surveillance Survey
Introduction: Patients with chronic obstructive pulmonary disease (COPD) are at increased risk for influenza-related morbidity and mortality. Influenza vaccination is known to decrease influenza incidence, severity, hospitalizations, and mortality. Identification of barriers to influenza vaccination among patients with COPD may aid in efforts to increase vaccination rates. This study aims to identify predictors of influenza vaccination in COPD patients.
- 1 January 2016
- Published by COPD Foundation in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
- Vol. 3 (3) , 620-627
Open AccessIdentification of Barriers to Influenza Vaccination in Patients with Chronic Obstructive Pulmonary Disease: Analysis of the 2012 Behavioral Risk Factors Surveillance Survey
Introduction: Patients with chronic obstructive pulmonary disease (COPD) are at increased risk for influenza-related morbidity and mortality. Influenza vaccination is known to decrease influenza incidence, severity, hospitalizations, and mortality. Identification of barriers to influenza vaccination among patients with COPD may aid in efforts to increase vaccination rates. This study aims to identify predictors of influenza vaccination in COPD patients.